액섬 테라퓨틱스(AXSM) Three months ended June 30, 2026 실적 분석

30초 요약

1. 1

   매출은 전년 같은 기간보다 45.5% 늘었어요

2. 2

   GAAP 희석 EPS는 전년 같은 기간보다 줄었어요

3. 3

   영업이익은 전년 같은 기간보다 줄었어요

4. 4

   일반회계 기준으로는 5,131만 달러 순손실이에요.

회사가 밝힌 숫자

사업 지표

• AUVELITY 순제품매출$180.3 million

  원문: “AUVELITY net product sales were $180.3 million for the second quarter of 2026, representing 51% year-over-year growth.”

• SUNOSI 순제품매출$35.8 million

  원문: “SUNOSI net product revenue was $35.8 million for the second quarter of 2026, representing 20% year-over-year growth, which consisted of $33.8 million in net product sales, $1.5 million in royalty revenue associated with SUNOSI sales in out-licensed territories, and $0.5 million in milestone revenue.”

• SYMBRAVO 순제품매출$2.3 million

  원문: “SYMBRAVO net product sales were $2.3 million for the second quarter of 2026, representing 461% year-over-year growth.”

• 총 순제품매출 증가율46%

  원문: “Total net product revenue was $218.4 million for the second quarter of 2026, representing 46% year-over-year growth.”

• AUVELITY 처방 증가율(전년 대비)34%

  원문: “Approximately 266,000 total prescriptions were written for AUVELITY in the second quarter of 2026, representing year-over-year and quarter-over-quarter increases of 34% and 12%, respectively.”

• SUNOSI 처방 증가율(전년 대비)14%

  원문: “Approximately 61,000 prescriptions were written for SUNOSI in the U.S. in the second quarter of 2026, a 14% increase compared to the same period in 2025, and an 8% increase compared to the first quarter of 2026.”

자주 묻는 질문